The short version of dihexa fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-17. Anything still debated is marked as such rather than presented as settled.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Most proteins fold into unique 3D structures. The shape into which a protein naturally folds is known as its native conformation. Although many proteins can fold unassisted, simply through the chemical properties of their amino acids, others require the aid of molecular chaperones to fold into their native states. Biochemists often refer to four distinct aspects of a protein's structure:
The term "penam" is used to describe the common core skeleton of a member of the penicillins. This core has the molecular formula R-C9H11N2O4S, where R is the variable side chain that differentiates the penicillins from one another. The penam core has a molar mass of 243 g/mol, with larger penicillins having molar mass near 450—for example, cloxacillin has a molar mass of 436 g/mol. 6-APA (C8H12N2O3S) forms the basic structure of penicillins. It is made up of an enclosed dipeptide formed by the condensation of L-cysteine and D-valine. This results in the formations of β-lactam and thiazolidinic rings. The key structural feature of the penicillins is the four-membered β-lactam ring; this structural moiety is essential for penicillin's antibacterial activity. The β-lactam ring is itself fused to a five-membered thiazolidine ring. The fusion of these two rings causes the β-lactam ring to be more reactive than monocyclic β-lactams because the two fused rings distort the β-lactam amide bond and therefore remove the resonance stabilisation normally found in these chemical bonds. An acyl side side chain attached to the β-lactam ring. A variety of β-lactam antibiotics have been produced following chemical modification from the 6-APA structure during synthesis, specifically by making chemical substitutions in the acyl side chain. For example, the first chemically altered penicillin, methicillin, had substitutions by methoxy groups at positions 2' and 6' of the 6-APA benzene ring from penicillin G.
==== Phase I–II ==== A phase I safety trial began on 18 June 2020. On 4 September 2020, data on 76 participants in a phase I–II trial were published, indicating preliminary evidence of safety and an immune response. The results were challenged by international vaccine scientists as being incomplete, suspicious, and unreliable when identical data were reported for many of the trial participants, but the authors responded that there was a small sample size of nine, and the measured results of titration could only take discrete values (800, 1600, 3200, 6400). Coupled with the observation that values tended to reach a plateau after three to four weeks, they contend that it is not unlikely that several participants would show identical results for days 21 to 28.
Whether an offender displayed viciousness during the time of the commission of the offence of murder; Whether an offender demonstrated a blatant disregard for human life at the time of the killing; and Whether the offender's actions sparked an outrage of the feelings of the community. In Kho's case, the majority three of the five judges were satisfied that Kho, who had used a tree branch to bash Cao's head repeatedly (resulting in a completely shattered skull that caused Cao to die in a coma six days after the attack), had demonstrated both a blatant disregard for human life and viciousness while committing the crime, and Kho's actions were such that they had outraged the feelings of the community. Due to this, Kho was once again given the death penalty and he was eventually hanged on 20 May 2016, at 3:30 pm after his appeal for a stay of execution was dismissed that same morning, a rare occurrence of an execution not carried out at dawn on Friday. Consequently, the guiding principles from Kho's case also impacted several subsequent murder cases and influenced the sentencing or appeal outcomes of these murder cases, which include the 2010 Kallang slashing, the 2016 Gardens by the Bay murder, the 2016 Circuit Road murder, the 2016 Azlin Arujunah case and the 2013 murder of Dexmon Chua Yizhi, etc.
The consulting surgeon on the repeat surgery may not inform the first surgeon of the recurrence. The time it takes for a recurrent tumor to be visible to the patient might be 5 or more years. Quoted "cure" rates must be looked upon with the understanding that a 5-year cure rate might not necessarily be correct. As basal-cell carcinoma is a very slowly progressing tumor, a 5-year no recurrence rate might not be adequate. A longer follow-up might be needed to detect a slow-growing tumor left in the surgical scar. Poor training of the surgeon/pathologist/histotechnologist. While Mohs surgery is essentially a technical method of tissue handling and processing, the skill and training of the surgeon can greatly affect the outcome. Success requires a foundation of good tissue handling, good surgical skill, and hemostasis, based on the tissue processing and staining technique. A surgeon without a good histotechnologist does not have access to sufficiently high-quality information about the cancer, and a histotechnologist without a good surgeon can not produce quality slides. Originally, surgeons learned the procedure by spending a few hours to several months with Mohs or during their residencies. Today, many Mohs surgeons complete a fellowship after their dermatology residency, spending hundreds of hours observing and performing Mohs surgery under the careful supervision of highly experienced Mohs surgeons. This is the most comprehensive and thorough method of learning Mohs surgery. Others learn the technique in their dermatology residencies and through courses and preceptorships.
Sources: en.wikipedia.org
=== Soviet disintegration === Political scientist Alex Pravda frames the Soviet collapse as unfolding in two acts: an initial phase, from 1989 to 1990, driven by smaller republics in the Baltic and Caucasus seeking sovereignty, followed by a second, from late 1990 through 1991, in which the defection of larger republics—Ukraine and, decisively, Russia under Boris Yeltsin—eroded the center's capacity to hold the union together. For Pravda, the USSR's demise was overwhelmingly domestic in origin, driven by ethnic nationalist movements that flourished under perestroika's liberalized conditions and were seized upon by republican elites contesting a Kremlin weakened by economic crisis; the international dimension of the Cold War's end played, in his assessment, only a secondary role. The collapse of the Eastern European governments with Gorbachev's tacit consent inadvertently encouraged several Soviet republics to seek greater independence from Moscow's rule. Agitation for independence in the Baltic states led to first Lithuania, and then Estonia and Latvia, declaring their independence. Disaffection in the other republics was met by promises of greater decentralization. More open ballots led to the election of candidates opposed to the Communist Party of the Soviet Union, but it also contributed to party fragmentation and presidentialism, which complicated democratic transition. Washington's confidence in the Soviet Union's survival outlasted Moscow's own. Visiting Kiev on 1 August 1991, George Bush Sr.
== Conservation treatment == The treatment of waterlogged wood should be undertaken by a professional conservator who understands how materials degrade and how the introduction of new materials might affect or at worst accelerate the degradation process. One of the largest issues with treatment on waterlogged wood is finding a way to remove the water in the wood but keep the water that is part of the material. Preventing cell wall collapse (which causes shrinking, cracking, and further damage) of the waterlogged wood while drying is the largest struggle and main goal of treatment. Some commonly used treatments include the polyethylene glycol (PEG) method, sucrose method, acetone-rosin method, alcohol-ether method, camphor-alcohol method, freeze drying, and silicone oil treatment, or various combinations.
== Prevention == There is ongoing research for methods to prevent type 1 diabetes. The development of diabetes symptoms can be delayed in some people who are at high risk of developing the disease. In 2022, the FDA approved an intravenous injection of teplizumab to delay the progression of type 1 diabetes in those older than eight who have already developed diabetes-related autoantibodies and problems with blood sugar control. In that population, the anti-CD3 monoclonal antibody teplizumab can delay the development of type 1 diabetes symptoms by around two years. In addition to anti-CD3 antibodies, several other immunosuppressive agents have been trialled to prevent beta cell destruction. Large trials of cyclosporine treatment suggested that cyclosporine could improve insulin secretion in those recently diagnosed with type 1 diabetes; however, people who stopped taking cyclosporine rapidly stopped making insulin, and cyclosporine's kidney toxicity and increased risk of cancer prevented people from using it long-term. Several other immunosuppressive agents – prednisone, azathioprine, anti-thymocyte globulin, mycophenolate, and antibodies against CD20 and IL2 receptor α – have been the subject of research. None has provided lasting protection from the development of type 1 diabetes. There have also been clinical trials attempting to induce immune tolerance by vaccination with insulin, GAD65, and various short peptides targeted by immune cells during type 1 diabetes; none have yet delayed or prevented development of disease.
== Plot == As the Federation Starship Enterprise approaches the planet Omega IV, the USS Exeter is found orbiting it. Captain Kirk, First Officer Spock, Dr. McCoy and Lt. Galloway beam over to the Exeter to investigate. They find the ship deserted, save for a few uniforms that are covered with a crystalline substance found to be human remains. The ship's logs reveal that the Exeter's crew died from an infectious disease that had been brought from the planet, and that Enterprise's landing party is now infected and must beam down to the planet if they are to survive. Kirk's party beams down to the last coordinates stored in the Exeter's computer. There, they discover Exeter Captain Ron Tracey (Morgan Woodward). Tracey explains that he had been on the planet when the disease had ravaged his ship, stranding him. He says he has discovered that remaining on the planet confers immunity to the disease. He then reveals that the villagers he is living with on the planet, known as "Kohms", are at war with "savages" called "Yangs". After a Yang attack, Spock investigates the field of battle and finds evidence that Tracey has been helping the Kohms, in violation of the Prime Directive. Kirk tries to contact the Enterprise, but is prevented by Tracey, who tries to justify his violation by revealing that the planet’s natives are not only immune to the mysterious disease, but have also developed lifespans of over 1000 years. Tracey orders McCoy to investigate the secret of their longevity and has Kirk and Spock locked up in a crude jail with two Yang prisoners, one male and one female.
==== Orthodox Christian heritage ==== Among the first Christian missionaries to arrive in the Aleutian Islands was a party of ten Russian Orthodox monks and priests, who arrived in 1793. Within two years, a monk named Herman was the only survivor of that party. He settled on Spruce Island, near Kodiak Island, and often defended the rights of the Aleuts against the Russian trading companies. He is now known in the Orthodox Church as Saint Herman of Alaska. Another early Christian missionary of the Russian Orthodox Church was Father Veniaminov who arrived in Unalaska in 1824. He was named Bishop Innokentii in 1840 and moved to Sitka. He is now known in the Orthodox Church as Saint Innocent of Alaska. The principal settlements were on Unalaska Island. The oldest was Iliuliuk (also called Unalaska), settled in 1760–1775, with a customs house and an Orthodox church.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.